Business
Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution
Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestonesNEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces it has successfully canceled all remaining Series A Warrants pursuant to its letter agreements with the holders of
About this update from Incannex Healthcare Inc.
[{"type":"image","alt":"Incannex Healthcare","displaySize":"","headline":null,"caption":"Incannex Healthcare","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JtZ_G8jXkVENc6BFL9UpGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/27f6059234ed425fa359634ca773e7f7","width":300,"height":50}},"lazy":false},{"type":"text","content":"Capital structure streamlined and potential dilution from Series A Warrants eliminated ahead of key Phase 2 clinical milestones","length":127,"tagName":"p"},{"type":"text","content":"NEW YORK and MELBOURNE, Australia, June 12, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces it has successfully canceled all remaining Series A Warrants pursuant to its letter agreements with the holders of the Series A Warrants, having raised the full amount of capital required to complete the cancellation through its At-The-Market (“ATM”) facility.","length":519,"tagName":"p"},{"type":"text","content":"This follows the Company’s May 28, 2025, announcement of binding agreements to cancel the final 172 million Series A Warrants in exchange for $12.2 million. Combined with a tranche canceled earlier in May, the initiative removes 347.2 million shares from potential future dilution, fully eliminating the Series A Warrant overhang.","length":330,"tagName":"p"},{"type":"text","content":"Incannex CEO Joel Latham commented, “Following increased market liquidity, we specifically utilized our ATM facility to fund the cancellation of all outstanding Series A Warrants. This eliminates a significant source of dilution and leaves Incannex with a clean capital structure ahead of key milestones, including the upcoming topline data readout from our Phase 2 RePOSA trial of IHL-42X for obstructive sleep apnea, expected in July 2025. This action reflects our commitment to disciplined capital management and long-term value creation for shareholders.”","length":559,"tagName":"p"},{"type":"text","content":"IHL-42X is being developed as a potential first-in-class oral therapy for obstructi...